Chelly, Jacques E.
Lacouture, Peter G.
Reyes, Christian Russel D.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety of Injectable HPβCD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials
https://doi.org/10.1007/s40266-018-0529-3
Documents that mention this clinical trial
Safety of Injectable HPβCD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials
https://doi.org/10.1007/s40266-018-0529-3
Documents that mention this clinical trial
Safety of Injectable HPβCD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials
https://doi.org/10.1007/s40266-018-0529-3
Funding for this research was provided by:
Pfizer
Article History
First Online: 1 March 2018
Compliance with Ethical Standards
:
: Jacques E. Chelly reports no conflict of interest. Peter G. Lacouture is a former employee of Hospira. Christian Russel D. Reyes is an employee of Pfizer and holds stock options with Pfizer.
: This study was sponsored by Hospira, Inc., which was acquired by Pfizer in September 2015. The three clinical trials included in the analysis were sponsored by Javelin Pharmaceuticals, Inc., which was acquired by Hospira, Inc. in 2010.
: All three trials included in this analysis adhered to the International Ethical Guidelines for Biomedical Research Involving Human Subjects, the International Conference on Harmonisation Good Clinical Practice guidelines, and the Helsinki Declaration. Each of the three trials was approved by the appropriate institutional review board and all patients provided written informed consent.